Pirfenidone to help prevent lung scarring in ARDS
Treatments studied
Part of Lungs & breathing clinical trials.
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older
- You have ARDS that started within 1 week of a known event or new/worsening breathing symptoms
- Chest X-ray shows problems in both lungs that aren’t fully explained by fluid buildup, collapsed lung, or lung nodules
- Your breathing is significantly impaired (oxygen levels with ventilation support meet the study cutoff)
- You fit an “inflammatory ARDS” pattern (at least one: high inflammation blood tests, needing medicines to support blood pressure, or certain blood chemistry signals like low bicarbonate or high lactate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Hear when a new Acute Respiratory Distress Syndrome (ARDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.